Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2021-03, Vol.44 (3), p.e61-e61
Hauptverfasser: Herring, Roselle A, Shojaee-Moradie, Fariba, Garesse, Robert, Stevenage, Mary, Jackson, Nicola, Fielding, Barbara A, Mendis, Agampodi, Johnsen, Sigurd, Umpleby, A Margot, Davies, Melanie, Russell-Jones, David L
Format: Artikel
Sprache:eng
Schlagworte:
Diabetes mellitus (insulin dependent)
Insulin
Ketoacidosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e61
container_issue 3
container_start_page e61
container_title Diabetes care
container_volume 44
creator Herring, Roselle A
Shojaee-Moradie, Fariba
Garesse, Robert
Stevenage, Mary
Jackson, Nicola
Fielding, Barbara A
Mendis, Agampodi
Johnsen, Sigurd
Umpleby, A Margot
Davies, Melanie
Russell-Jones, David L
description
doi_str_mv 10.2337/dci20-0072
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2491939785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2491939785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c240t-9d713ed3c42e0e41188f247c76871a8d5b8c55bcb6878debee31434130a6651d3</originalsourceid><addsrcrecordid>eNpdks1u1DAURiMEosPAhgdAV2JTkDL4L4lTVtVMaSsGUcEglpFj37SuPHGwHVB5Y96CzEzpgpWvpfMdXel-WfaSkgXjvHpntGUkJ6Rij7IZrXmRF4WQj7MZoaLOi7pmR9mzGG8JIUJI-TQ74rwkkrN6lv35gnHwfURIHpZ-u8U-ge_hAkOw_TVgAuUW8AmTar2zGs66DnWK4DtQPXw9X28YXPY3trXJBzheqUFdO9s5_9v2b2A17i0KrjBYb3apUz0mnCJxdLaH7zbdmKB-KTfpDKzwJzo_HLbo4CMmr7Q1PtoIE32FfnC4D8HmbkCgsLKqxYRx8TDBUgUERhh5L_gJo0zmjPLyefakUy7ii_t3nn37cLZZXuTrz-eXy9N1rpkgKa9NRTkargVDgoJSKTsmKl2VsqJKmqKVuiha3U5_abBF5FRwQTlRZVlQw-fZ8cE7BP9jxJiarY0anVM9-jE2TNTTjepKFhP6-j_01o-hn7bbUawiZTWJ59nbA6WDjzFg1wzBblW4ayhpdgVo9gVodgWY4Ff3yrHdonlA_12c_wUgZ6lf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2492706741</pqid></control><display><type>article</type><title>Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Herring, Roselle A ; Shojaee-Moradie, Fariba ; Garesse, Robert ; Stevenage, Mary ; Jackson, Nicola ; Fielding, Barbara A ; Mendis, Agampodi ; Johnsen, Sigurd ; Umpleby, A Margot ; Davies, Melanie ; Russell-Jones, David L</creator><creatorcontrib>Herring, Roselle A ; Shojaee-Moradie, Fariba ; Garesse, Robert ; Stevenage, Mary ; Jackson, Nicola ; Fielding, Barbara A ; Mendis, Agampodi ; Johnsen, Sigurd ; Umpleby, A Margot ; Davies, Melanie ; Russell-Jones, David L</creatorcontrib><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dci20-0072</identifier><identifier>PMID: 33608329</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Diabetes mellitus (insulin dependent) ; Insulin ; Ketoacidosis</subject><ispartof>Diabetes care, 2021-03, Vol.44 (3), p.e61-e61</ispartof><rights>Copyright American Diabetes Association Mar 1, 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c240t-9d713ed3c42e0e41188f247c76871a8d5b8c55bcb6878debee31434130a6651d3</cites><orcidid>0000-0002-8267-6236 ; 0000-0002-9490-2480</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33608329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herring, Roselle A</creatorcontrib><creatorcontrib>Shojaee-Moradie, Fariba</creatorcontrib><creatorcontrib>Garesse, Robert</creatorcontrib><creatorcontrib>Stevenage, Mary</creatorcontrib><creatorcontrib>Jackson, Nicola</creatorcontrib><creatorcontrib>Fielding, Barbara A</creatorcontrib><creatorcontrib>Mendis, Agampodi</creatorcontrib><creatorcontrib>Johnsen, Sigurd</creatorcontrib><creatorcontrib>Umpleby, A Margot</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><creatorcontrib>Russell-Jones, David L</creatorcontrib><title>Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><subject>Diabetes mellitus (insulin dependent)</subject><subject>Insulin</subject><subject>Ketoacidosis</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdks1u1DAURiMEosPAhgdAV2JTkDL4L4lTVtVMaSsGUcEglpFj37SuPHGwHVB5Y96CzEzpgpWvpfMdXel-WfaSkgXjvHpntGUkJ6Rij7IZrXmRF4WQj7MZoaLOi7pmR9mzGG8JIUJI-TQ74rwkkrN6lv35gnHwfURIHpZ-u8U-ge_hAkOw_TVgAuUW8AmTar2zGs66DnWK4DtQPXw9X28YXPY3trXJBzheqUFdO9s5_9v2b2A17i0KrjBYb3apUz0mnCJxdLaH7zbdmKB-KTfpDKzwJzo_HLbo4CMmr7Q1PtoIE32FfnC4D8HmbkCgsLKqxYRx8TDBUgUERhh5L_gJo0zmjPLyefakUy7ii_t3nn37cLZZXuTrz-eXy9N1rpkgKa9NRTkargVDgoJSKTsmKl2VsqJKmqKVuiha3U5_abBF5FRwQTlRZVlQw-fZ8cE7BP9jxJiarY0anVM9-jE2TNTTjepKFhP6-j_01o-hn7bbUawiZTWJ59nbA6WDjzFg1wzBblW4ayhpdgVo9gVodgWY4Ff3yrHdonlA_12c_wUgZ6lf</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Herring, Roselle A</creator><creator>Shojaee-Moradie, Fariba</creator><creator>Garesse, Robert</creator><creator>Stevenage, Mary</creator><creator>Jackson, Nicola</creator><creator>Fielding, Barbara A</creator><creator>Mendis, Agampodi</creator><creator>Johnsen, Sigurd</creator><creator>Umpleby, A Margot</creator><creator>Davies, Melanie</creator><creator>Russell-Jones, David L</creator><general>American Diabetes Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8267-6236</orcidid><orcidid>https://orcid.org/0000-0002-9490-2480</orcidid></search><sort><creationdate>202103</creationdate><title>Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136</title><author>Herring, Roselle A ; Shojaee-Moradie, Fariba ; Garesse, Robert ; Stevenage, Mary ; Jackson, Nicola ; Fielding, Barbara A ; Mendis, Agampodi ; Johnsen, Sigurd ; Umpleby, A Margot ; Davies, Melanie ; Russell-Jones, David L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c240t-9d713ed3c42e0e41188f247c76871a8d5b8c55bcb6878debee31434130a6651d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Diabetes mellitus (insulin dependent)</topic><topic>Insulin</topic><topic>Ketoacidosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herring, Roselle A</creatorcontrib><creatorcontrib>Shojaee-Moradie, Fariba</creatorcontrib><creatorcontrib>Garesse, Robert</creatorcontrib><creatorcontrib>Stevenage, Mary</creatorcontrib><creatorcontrib>Jackson, Nicola</creatorcontrib><creatorcontrib>Fielding, Barbara A</creatorcontrib><creatorcontrib>Mendis, Agampodi</creatorcontrib><creatorcontrib>Johnsen, Sigurd</creatorcontrib><creatorcontrib>Umpleby, A Margot</creatorcontrib><creatorcontrib>Davies, Melanie</creatorcontrib><creatorcontrib>Russell-Jones, David L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herring, Roselle A</au><au>Shojaee-Moradie, Fariba</au><au>Garesse, Robert</au><au>Stevenage, Mary</au><au>Jackson, Nicola</au><au>Fielding, Barbara A</au><au>Mendis, Agampodi</au><au>Johnsen, Sigurd</au><au>Umpleby, A Margot</au><au>Davies, Melanie</au><au>Russell-Jones, David L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2021-03</date><risdate>2021</risdate><volume>44</volume><issue>3</issue><spage>e61</spage><epage>e61</epage><pages>e61-e61</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><cop>United States</cop><pub>American Diabetes Association</pub><pmid>33608329</pmid><doi>10.2337/dci20-0072</doi><orcidid>https://orcid.org/0000-0002-8267-6236</orcidid><orcidid>https://orcid.org/0000-0002-9490-2480</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-5992
ispartof Diabetes care, 2021-03, Vol.44 (3), p.e61-e61
issn 0149-5992
1935-5548
language eng
recordid cdi_proquest_miscellaneous_2491939785
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Diabetes mellitus (insulin dependent)
Insulin
Ketoacidosis
title Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A37%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20Comment%20on%20Herring%20et%20al.%20Metabolic%20Effects%20of%20an%20SGLT2%20Inhibitor%20(Dapagliflozin)%20During%20a%20Period%20of%20Acute%20Insulin%20Withdrawal%20and%20Development%20of%20Ketoacidosis%20in%20People%20With%20Type%201%20Diabetes.%20Diabetes%20Care%202020;43:2128-2136&rft.jtitle=Diabetes%20care&rft.au=Herring,%20Roselle%20A&rft.date=2021-03&rft.volume=44&rft.issue=3&rft.spage=e61&rft.epage=e61&rft.pages=e61-e61&rft.issn=0149-5992&rft.eissn=1935-5548&rft_id=info:doi/10.2337/dci20-0072&rft_dat=%3Cproquest_cross%3E2491939785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2492706741&rft_id=info:pmid/33608329&rfr_iscdi=true